Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (9.000.000 €): Untersuchen von Mechanismen und Modellen Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain Hor 01.01.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Untersuchen von Mechanismen und Modellen Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease). The related key deliverables will be as follows: 1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease. 2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states. 3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms. 4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents. 5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems. 6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS. 7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.


Geförderte Unternehmen:

Firmenname Förderungssumme
Aarhus Universitet 553.966 €
Academisch Ziekenhuis Leiden 273.504 €
AIT Austrian Institute OF Technology GmbH 403.694 €
Artemis BIO-Support B.V. 290.380 €
Cardiff University 326.110 €
Fujifilm Cellular Dynamics Inc. 0,00 €
H. Lundbeck AS 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Kobenhavns Universitet 602.199 €
Medizinische Universitaet Wien 208.599 €
Mimetas B.V. 251.813 €
Neuway Pharma GmbH 112.511 €
Novartis Pharma AG 0,00 €
Novo Nordisk A/S 0,00 €
Pfizer Ltd. 0,00 €
Pharmacoidea Fejleszto ES Szolgaltato kft. 300.059 €
Ruprecht-Karls-Universitaet Heidelberg 290.188 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Stichting Amsterdam UMC 279.583 €
Stiftung Tieraerztliche Hochschule Hannover 290.313 €
The Chancellor, Masters and Scholars of the University of Oxford 2.218.291 €
The Open University 232.284 €
The University of Sheffield 249.305 €
Universita Degli Studi Di Modena E Reggio Emilia 67.565 €
Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat 293.719 €
Universitaetsmedizin DER Johannes Gutenberg-Universitaet Mainz 288.661 €
University of Dundee 354.009 €
Uppsala Universitet 1.113.250 €

Quelle: https://cordis.europa.eu/project/id/807015

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.